Current Management of Diabetes - PowerPoint PPT Presentation

About This Presentation
Title:

Current Management of Diabetes

Description:

Sulfonylureas Drug Dose Side effects Tolbutamide Restinon 500-2000mg Od-Bid Weight gain hypoglycemia Glibenclamide Daonil 5mg 15-20 mg Od-Bid Weight gain ... – PowerPoint PPT presentation

Number of Views:183
Avg rating:3.0/5.0
Slides: 37
Provided by: Zekeri79
Category:

less

Transcript and Presenter's Notes

Title: Current Management of Diabetes


1
(No Transcript)
2
Current Management of Diabetes
Introduction to Primary Care a course of the
Center of Post Graduate Studies in FM
PO Box 27121 Riyadh 11417 Tel 4912326 Fax
4970847
3
Aim
  • having information on assessing symptoms and
    signs.
  • developing management plans for diabetes.

4
Objectives
  • At the end of this session, the trainees should
    be able to-
  • list diagnostic criteria for DM
  • describe how to differentiate Type I II DM
  • explain symptoms and signs of diabetes
  • discuss the evidence for lifestyle changes
  • describe the indications, contraindications, and
    side effects of antidiabetic agents

5
DM in Saudi Arabia
  • Lifestyle Changes
  • Social cultural changes
  • Prevalence
  • Diabetes mellitus as a health problem in Saudi
    Arabia
  • prevalence of DM is 23.7 according to Dr. Al
    Nozha study (SMJ 2004)
  • 1 / 4 of adults gt 30 yr are diabetics.
  • 36 Foot Amputation / day, at Riyadh.

6
D.M in Saudi Arabia cont..
  • Cost Impacts .
  • Psychological impact.
  • Family Social impact .
  • Decreased Productivity .
  • Sick leaves.
  • Work Absence .
  • Economical Costs .

7
Etiologic classification of diabetes mellitus
I- Type 1 diabetes
II- Type 2 diabetes.
III- Other specific types.
IV- Gestational diabetes mellitus.
8
Etiologic Classification of Diabetes Mellitus
  • Type 1
  • b-cell destruction with lack of insulin .
  • has absolute insulin deficiency
  • predisposed to develop ketoacidosis
  • insulin is required for survival.

9
Etiologic Classification of Diabetes Mellitus
  • Type 2
  • has relative insulin deficiency combined with
    defects in insulin action.
  • is the most common form of diabetes, accounting
    for 9095 of the disease
  • is most often found in overweight individuals.

Narayan K, Boyle J, Thompson T, Sorensen S,
Williamson D (2003). "Lifetime risk for diabetes
mellitus in the United States". JAMA 290 (14)
188490. doi10.1001/jama.290.14.1884.
10
Risk Factors for Type 2 DM
  • Modifiable
  • Overweight and obesity
  • Sedentary lifestyle
  • Previously identified IGT and IFG
  • Metabolic syndrome
  • Diatery factors
  • Intrauterine environment
  • Inflamation
  • Non- Modifiable
  • Family history
  • Age
  • Gender
  • History of GDM
  • Polycystic ovary syndrome (PCO)

11
(No Transcript)
12
Symptoms Signs
  • Classical symptoms
  • Unusual thirst (Polydipsia)
  • Frequent urination (Polyuria)
  • Unusual weight loss
  • Other symptoms
  • Extreme fatigue or lack of energy
  • Unusually hungry
  • Moody irritable
  • Blurred vision
  • Have recurrent infections
  • Wounds and bruises that are slow to heal
  • Get a lot of yeast infections
  • Have tingling or numbness in the hands and/or
    feet
  • Patients may present with a variety of symptoms
    or even symptomless

13
Criteria to diagnosis diabetes
  • FPG gt126 mg/dl (7.0 mmol/l)
  • ( Fasting is defined as no caloric intake for at
    least 8 h) OR
  • Symptoms of diabetes and a casual plasma glucose
    gt 200 mg/dl (11.1 mmol/l) OR
  • 2-h plasma glucose gt 200 mg/dl (11.1 mmol/l)
    during an OGTT.
  • ( The test should be performed as described by
    the W H O (using a glucose load containing the
    equivalent of 75g anhydrous glucose dissolved in
    water)).

14
Diagnosis of Diabetes Plasma Glucose Cutoff
Points
2- Hour BS on OGTT FBS
mg/dl mg/ dl categories
lt 140 lt 100 Normal
_ gt 100 and lt 126 IFG
gt 140 and lt 200 _ IGT
gt 200 gt 126 Diabetes
If without symptoms, there should be more than
one measurement in order to diagnose.
.
15
Diagnosis of gestational DM
16
(No Transcript)
17
First visit evaluation
  • History taking and clinical assessment
  • Physical examination
  • Height and weight measurement .
  • Blood pressure determination .
  • Fundoscopic examination
  • Oral examination
  • Thyroid palpation
  • Cardiac examination

18
First visit evaluation
  • Physical examination
  • Abdominal examination (e.g., for hepatomegaly)
  • Evaluation of pulses by palpation
  • Hand/finger examination
  • Foot examination
  • Skin examination
  • Neurological examination
  • Signs of diseases that can cause secondary
    diabetes (e.g., hemochromatosis, pancreatic
    disease)

19
First visit evaluation
  • Laboratory evaluation
  • HBA1c
  • Fasting lipid profile
  • Test for microalbuminuria
  • Serum creatinine in adults .
  • Thyroid-stimulating hormone (if indicated)
  • Electrocardiogram in adults (if indicated)
  • Urinalysis for ketones and protein

20
Management Goals
  • Annual visits and examinations should be done
    regularly
  • Eliminate symptoms and improve well-being
  • Prevent and retard microvascular complications
  • optimize glycemic control
  • target blood pressure levels
  • Reduce macrovascular events
  • optimize glycemic control
  • target blood pressure levels
  • target lipid levels

21
(No Transcript)
22
Summary of recommendations for adults with
Diabetes
  • Parameter Target Value
  • HbA1c lt 7
  • pre-prandial plasma glucose 70 - 130 mg/dL
  • post-prandial plasma glucose lt 180 mg/dL
  • Blood pressure lt 130/80
    mmHg
  • LDL- cholesterol lt 100 mg/dL
    (lt2.6 mmol/l)
  • HDL- cholesterol gt 40 mg/dL (1 mmol/l) for
    men gt 50 mg/dL (1.3 mmol/l) for wom.
  • Triglycerides lt 150 mg/dL (17 mmol/l)

ADA 2009
23
Key concepts in setting glycemic goals
  • Goals should be individualized based on
  • ? duration of diabetes
  • ? pregnancy status
  • ? age
  • ? co-morbid conditions
  • ? hypoglycemia unawareness
  • ? individual patient considerations

24
Follow up
25
Things to keep in mind during management of
Diabetes
  • Type 2 Deterioration of beta cells over time
  • Increasing prevalence with increasing risk
    factors, e.g obesity
  • Hyperglycemia affects morbidity, mortality and
    resources
  • Tight glycemic control with insulin may reduce
    costly complications
  • 30 to 40 of patients ultimately require insulin

26
Non-pharmacologic Therapy for DM Lifestyle
therapeutic modifications
  • Diet
  • Improved food choices
  • Spacing meals
  • Individualized carbohydrate content
  • Moderate calorie restriction
  • Exercise
  • improve blood glucose control
  • reduce cardiovascular risk factors
  • contribute to weight loss.
  • improve well-being.

27
Nutritional recommendations for DM patients
  • Protein to provide 10-20 of kcal/day
  • Saturated fat to provide lt 10 of kcal/day (lt 7
    for those with elevated LDL).
  • Polyunsaturated fat to provide lt 10 of kcal.
  • Remaining calories to be divided between
    carbohydrate monounsaturated fat, based on
    medical needs personal tolerance.
  • Use of caloric sweeteners is acceptable.

28
Considerations in Pharmacologic Treatment of
Diabetes
  • Complications/tolerability
  • Frequency of hypoglycemia
  • Compliance/complexity of regimen
  • Cost

29
(No Transcript)
30
(No Transcript)
31
(No Transcript)
32
(No Transcript)
33
(No Transcript)
34
Sulfonylureas
Drug Dose Side effects
Tolbutamide Restinon 500-2000mg Od-Bid Weight gain hypoglycemia
Glibenclamide Daonil 5mg 15-20 mg Od-Bid Weight gain Hypoglycemia
Gliclazide Diamicron 80mg 40-320mg Od-Bid Weight gain hypoglycemia
Glipizide Minidiab 5mg 2.5-20mg Od Weight gain hypoglycemia
Glimerpiride Amaryl 1,2,4 mg 1-8mg Od Weight gain hypoglycemia
35
Drug Dose Side effects Drug class
Metformin Glocophage 500-850mg 1000-2550mg Bid-Tid Diarrhea Lactic acidosis Biguanides ? hepatic glucose production
Acrobose Glucobay 50-100 mg 150-300 mg Tid Gas , Abdominal pain, Diarrhea a Glucosidase inhibitors ? intestinal absorption
Rosiglitazone Avandia 2,4,8 mg 4-8mg Od-Bid Oedema,weight gain,hepatic failure Thiazolidinediones ? preipheral glucose disposal
Repaglinide Novonorm 0.5,1,2 mg 1.5-16mg Tid-Qid Weight gain hypoglycemia Meglitinides ? pancreatic insulin secretion
36
THANK YOU
Write a Comment
User Comments (0)
About PowerShow.com